{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:45:46Z","timestamp":1789152346002,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010434","name":"Caixabank SA","doi-asserted-by":"publisher","award":["LCF\/PR\/HR21\/52410022"],"award-info":[{"award-number":["LCF\/PR\/HR21\/52410022"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.prp.2025.156028","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T02:13:51Z","timestamp":1747620831000},"page":"156028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["FGFR3 immunohistochemistry as a surrogate biomarker for FGFR3 alterations in urothelial carcinoma"],"prefix":"10.1016","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5710-958X","authenticated-orcid":false,"given":"Claudia","family":"Mercader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Calderon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Ribera-Cortada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Trias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Cobo-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Alcaraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Mengual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Rodr\u00edguez-Carunchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Vilaseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.prp.2025.156028_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.prp.2025.156028_bib2","series-title":"Bladder pathology","author":"Cheng","year":"2012"},{"issue":"9","key":"10.1016\/j.prp.2025.156028_bib3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrc1697","article-title":"Urothelial tumorigenesis: a tale of divergent pathways","volume":"5","author":"Wu","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2025.156028_bib4","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. EAU Guidelines Office, Arnhem, The Netherlands; 2024."},{"issue":"1","key":"10.1016\/j.prp.2025.156028_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2025.156028_bib6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann. Oncol."},{"issue":"21","key":"10.1016\/j.prp.2025.156028_bib7","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"6_","key":"10.1016\/j.prp.2025.156028_bib8","volume":"41","author":"Vilaseca","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156028_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/12615","article-title":"Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas","volume":"23","author":"Cappellen","year":"1999","journal-title":"Nat. Genet"},{"issue":"4","key":"10.1016\/j.prp.2025.156028_bib10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.eururo.2007.12.026","article-title":"Prediction of progression of non\u2013muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study","volume":"54","author":"Burger","year":"2008","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.prp.2025.156028_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eururo.2010.05.043","article-title":"Molecular grade (FGFR3\/MIB-1) and EORTC risk scores are predictive in primary non\u2013muscle-invasive bladder cancer","volume":"58","author":"van Rhijn","year":"2010","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.prp.2025.156028_bib12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.juro.2011.09.008","article-title":"The FGFR3 mutation is related to favorable pT1 bladder cancer","volume":"187","author":"van Rhijn","year":"2012","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.prp.2025.156028_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J. Pathol."},{"issue":"5","key":"10.1016\/j.prp.2025.156028_bib14","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3892\/ol.2015.3691","article-title":"Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer","volume":"10","author":"Poyet","year":"2015","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.prp.2025.156028_bib15","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.euf.2020.08.001","article-title":"Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma","volume":"7","author":"Necchi","year":"2021","journal-title":"Eur. Urol. Focus"},{"issue":"2","key":"10.1016\/j.prp.2025.156028_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.eururo.2020.05.039","article-title":"Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature","volume":"78","author":"Hassler","year":"2020","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.prp.2025.156028_bib17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","article-title":"Comprehensive genomic characterization of upper tract urothelial carcinoma","volume":"72","author":"Moss","year":"2017","journal-title":"Eur. Urol."},{"issue":"A","key":"10.1016\/j.prp.2025.156028_bib18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3889\/oamjms.2023.11372","article-title":"Molecular and immunohistochemical assessment of fibroblast growth factor receptor 3 (FGFR3) gene as a survival time predictor in bladder cancer patients","volume":"11","author":"Mamdouh","year":"2023","journal-title":"Open Access Maced. J. Med Sci."},{"issue":"4","key":"10.1016\/j.prp.2025.156028_bib19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/cam4.262","article-title":"FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder","volume":"3","author":"Guancial","year":"2014","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.prp.2025.156028_bib20","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cncr.23212","article-title":"Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur","volume":"112","author":"Barbisan","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.prp.2025.156028_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4111\/kju.2010.51.2.94","article-title":"Expression of fibroblast growth factor receptor 3 in the recurrence of non-muscle-invasive urothelial carcinoma of the bladder","volume":"51","author":"Maeng","year":"2010","journal-title":"Korean J. Urol."},{"issue":"1","key":"10.1016\/j.prp.2025.156028_bib22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1158\/1541-7786.MCR-14-0022","article-title":"Alteration of cell\u2013cell and cell\u2013matrix adhesion in urothelial cells: an oncogenic mechanism for mutant FGFR3","volume":"13","author":"di Martino","year":"2015","journal-title":"Mol. Cancer Res."},{"issue":"2 Pt 1","key":"10.1016\/j.prp.2025.156028_bib23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1078-0432.459.11.2","article-title":"Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth","volume":"11","author":"G\u00f3mez-Rom\u00e1n","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.prp.2025.156028_bib24","first-page":"967","article-title":"Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and\/or non-invasive lesions","volume":"12","author":"Matsumoto","year":"2004","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.prp.2025.156028_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ejso.2005.11.018","article-title":"FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer","volume":"32","author":"Mhawech-Fauceglia","year":"2006","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"issue":"51","key":"10.1016\/j.prp.2025.156028_bib26","doi-asserted-by":"crossref","first-page":"30643","DOI":"10.1074\/jbc.270.51.30643","article-title":"Fibroblast Growth Factor Receptors (FGFRs) localize in different cellular compartments","volume":"270","author":"Johnston","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"ement 1","key":"10.1016\/j.prp.2025.156028_bib27","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1097\/PGP.0000000000000518","article-title":"Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists","volume":"38","author":"Soslow","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"4","key":"10.1016\/j.prp.2025.156028_bib28","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s12253-020-00836-w","article-title":"Prognosis trend of grade 2 endometrioid endometrial carcinoma: toward grade 1 or 3?","volume":"26","author":"Khatib","year":"2020","journal-title":"Pathol. Oncol. Res."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825002201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825002201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:26:19Z","timestamp":1778747179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825002201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":28,"alternative-id":["S0344033825002201"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156028","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR3 immunohistochemistry as a surrogate biomarker for FGFR3 alterations in urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156028"}}